- Sales +148% y-o-y on recent orders, but -16% ABG/cons - Lower-than-expected Q2 terminal sales to c...
- Figures in line with pre-announcement - Aurdel a little softer than expected - Consensus EBIT esti...
Redeye state’s Safello’s Q2 2025 presented top-line headwinds with net sales of SEK130.
Redeye comments on Verve Group’s Q2 2025 results and the lowered full-year guidance.
Aspo reports Q2 results on Aug 18. Telko and Leipurin are on a steady track to improve more after la...
Redeye comments on EG7’s Q2-results which came in weaker than expected, with somewhat lower revenue ...
Marimekko’s domestic sales proved more resilient in Q2 than we expected while international growth w...
Redeye returns with positive estimate revisions following Bredband2's report that all in all, was so...
We lower 2025E adjusted EBIT by 10% yet keep 2026E-27E adjusted EBIT largely intact (+2%), as we fin...
Redeye retains its positive view of Transtema following a Q2 report roughly matching our expectation...
- Earnings disappointment in Q2, but strong cash flow - We lower our US and Germany EBIT estimates -...
- Solid top-line and normalising costs; Q2 EBITA +15% vs.
Redeye comments on Bredband2’s Q2 report which posted marginally stronger performance across the boa...
Robust growth continued as expected, though profitability fell slightly short of our estimates due t...
Redeye retains its positive view of Transtema following a Q2 report that aligns with our expectation...
Dovre’s project challenges have been extended, but Sweden and Finland should offer more opportunitie...
Redeye provides an update on Scandinavian ChemoTech following the Q2 2025 report.
Redeye comments on the 350MW asset management agreement, spread over 94 turbines, that was signed tw...
Taaleri's Q2 results came largely in line with our expectations on an underlying basis, owing to goo...
Redeye is encouraged by the NTAP for CERAMENT G used in trauma, as it aids in the company’s early-st...
